Publications

Abstract Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease predominantly of the small airways and parenchyma. COPD lungs exhibit an influx of circulating innate immune cells, which, when isolated, display impaired functions, including imbalanced protease secretion. In addition to immune cells, the extracellular matrix (ECM) plays a crucial role in COPD pathology. Remodeling […]

Abstract OBJECTIVES To investigate whether serum C1M and C2M, biochemical markers of synovial and cartilage tissue destruction, were associated with progression of joint damage in patients with early arthritis. METHODS 813 early arthritis patients (<6 months of symptoms, 82% with rheumatoid arthritis, 18% undifferentiated arthritis) from the prospective ESPOIR study were followed for 5 years. […]

Abstract BACKGROUND There is a need to identify peripheral biomarkers reflective of defined disease associated fibroblasts in Ulcerative Colitis (UC), with the aim of enabling clinical development approaches for novel-stromal-targeted therapeutics for individuals at risk for fibrostenotic complications. Additionally, longitudinal non-invasive biomarkers of tissue remodelling, fibroblast biology and pharmacodynamic measurements are needed in the clinic […]

Abstract BACKGROUND Given the heterogeneity of advanced chronic liver disease, assessing disease activity-related biomarkers could aid in classifying cirrhosis endotypes for better patient monitoring and treatment selection. AIM To investigate cirrhosis endotypes described by disease activity biomarkers related to fibrogenesis, immune cell activity, apoptosis, and systemic inflammation. METHODS The study included plasma EDTA samples from […]

Abstract Impaired gut barrier function may lead to progression of liver fibrosis in people with alcohol-related liver disease. The postbiotic ReFerm® can lower gut barrier permeability and may thereby  reduce fibrosis formation. Here, we report the results from an open-labelled, single centre randomized controlled trial where 56 patients with advanced, compensated, alcohol-related liver disease were assigned […]

Abstract Inflammatory Bowel Disease (IBD) is characterized by mucosal injury in the gastrointestinal (GI) tract. During an abnormal immune response in the GI tract, excessive secretion of immune-cell proteases occurs. Neutrophils are the first responders, infiltrating into the inflamed interstitial matrix, where type III collagen accumulates. We aimed to develop a biomarker that reflects early […]

Abstract BACKGROUND AND AIMS Crohn’s disease (CD) is characterized by progressive intestinal transmural damage, including fibrosis and strictures, which impair quality of life and require surgical intervention. No anti-stricture therapies are available, and no accurate biomarkers have been validated allowing prediction of strictures. Collagen fragments synthesis and remodeling show potential as markers of transmural disease […]

Abstract BACKGROUND Adjunctive host-directed therapies that modulate host immune responses to reduce excessive inflammation and prevent tissue damage in tuberculosis are being investigated. Macrolides, including azithromycin, were shown to possess anti-inflammatory and immune-modulatory effects in addition to their antibacterial effects. In the current trial, we investigated whether azithromycin enhances resolution of systemic and pulmonary inflammation […]

Abstract ObjectiveTo investigate how running, cycling, and sedentary cardiovascular stress impact biomarkers of cartilage turnover acutely in subjects with knee osteoarthritis (OA).DesignThis was a sequential, cross-over, clinical study. Forty subjects with primary knee OA underwent moderate-to-high-intensity cycling, running, and adrenaline infusion on separate days. Blood was sampled before, during, and at 6-time points after intervention. […]

Abstract PURPOSE There is an unmet need for new treatment options and biomarkers for patients with glioblastoma (GBM). Here we investigated three non-invasive biomarkers: type VI collagen degraded by granzyme B (C4G) and matrix metalloproteases (C4M), respectively, and ADAM10-degraded Tau (Tau-A). METHODS Biomarker levels in pre- and on-treatment serum samples from patients with recurrent GBM […]